Successful therapy of chronic graft-versus-host disease manifesting as pure red cell aplasia with single-agent rituximab.

摘要

Recently, Zaja et al,described the G1TMO experience with rituximab as therapy for chronic graft-versus-host disease (cGVHD). In their series, an encouraging overall response rate of 65% was observed, particularly among patients with cutaneous cGVHD. One patient with cGVHD manifesting as a pure red cell aplasia (PRCA) failed to demonstrate response. Only one other report regarding the efficacy of rituximab for cGVHD manifesting as PRCA has been published to date; here, we report a patient with PRCA as a manifestation of cGVHD who was successfully treated with single-agent rituximab.